SCHEMBL7248229

SCHEMBL7248229

NCC1(CNC(=O)Cc2ccccc2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 17/20 0.60
NPFFR2 Q9Y5X5 17/20 0.60
OPRK1 P41145 6/20 0.60
SIGMAR1 Q99720 2/20 0.52
OPRD1 P41143 3/20 0.52
OPRM1 P35372 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7251032 0.86 NPFFR1 (0.56) NPFFR1NPFFR2OPRK1OPRD1OPRM1
SCHEMBL7249859 0.86 NPFFR1 (0.52) NPFFR1NPFFR2OPRK1
SCHEMBL7249605 0.81 POLB (0.45)
SCHEMBL7249447 0.81 ALDH1A1 (0.44) NPFFR1NPFFR2
SCHEMBL7250646 0.81 ALDH1A1 (0.44)
SCHEMBL7248709 0.80 NPFFR1 (0.51) NPFFR1NPFFR2OPRK1
SCHEMBL7248648 0.80 ALDH1A1 (0.44)
SCHEMBL3334062 0.79 SIGMAR1 (0.61) SIGMAR1OPRM1
SCHEMBL7249154 0.79 CA1 (0.44)
SCHEMBL6079469 0.77 POLB (0.59) SIGMAR1OPRD1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1045834-A1 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS WARNER-LAMBERT COMPANY (US) 2000-10-25 EP claimed
WO-1999031057-A1 4(3)SUBSTITUTED-4(3)-AMINOMETHYL-(THIO)PYRAN OR -PIPERIDINE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS WARNER-LAMBERT COMPANY (US) 1999-06-24 WO claimed
US-6545022-B1 Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders PFIZER INC. 2003-04-08 US disclosed